Their last corporate presentation anticipated the NDA re-re-submission in 1Q2014.
They haven't spent a dime on anything other than getting this on drug to market. Shareholder meeting on September 19th to vote on name change and reverse split. That is a done deal. Then they will get relisted on Nasdaq. Also they need cash. Only have enough to make it "into 2014". There recent S-3 filing indicates they may raise up $100,000,000. My guess is that will happen after the reverse split and relisting.